4.3 Article

Clinical Manifestations and Treatment of Drug-induced Hepatotoxicity

Journal

CLINICS IN LIVER DISEASE
Volume 17, Issue 4, Pages 565-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2013.07.003

Keywords

Drug-induced liver injury; Drug-induced cholestasis; Drug-induced hepatocellular injury; Management of drug-induced liver injury

Ask authors/readers for more resources

With an increase of prescription medication and herbal supplement use, drug-induced liver injury (DILI) has become an increasingly important entity. Because DILI is a usually readily treatable condition, it is essential for providers to reach a diagnosis in a timely fashion. Unfortunately, varied clinical presentations, difficulties in establishing causality, and lack of a gold standard diagnostic criterion may make early diagnosis difficult. This article seeks to define commonly used terminology, describe common clinical presentations of DILI, provide an overview of current diagnostic criteria, and provide management guidelines.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
Article Gastroenterology & Hepatology

Autoimmune Hepatitis Pathophysiology

Zhou Yuming, Tang Ruqi, Merrill Eric Gershwin, Ma Xiong

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Primary Biliary Cholangitis Pathophysiology

Inbal Houri, Gideon M. Hirschfield

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Treatment of Primary Biliary Cholangitis including Transplantation

Yasameen Muzahim, Ali Wakil, Mehak Bassi, Nikolaos Pyrsopoulos

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis

Brian H. Horwich, Douglas T. Dieterich

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Treatment of Autoimmune Hepatitis

Aparna Goel, Paul Kwo

Summary: The goal of autoimmune hepatitis treatment is achieving clinical and biochemical remission. Standard care involves induction treatment with corticosteroids and gradual tapering of steroids. Alternatives to standard therapy can be considered for patients with intolerance or inadequate response. Treatment withdrawal is achievable in less than 20% of patients after 2 years of sustained remission, and liver transplantation should be considered for patients with progressive disease or complications.

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Systemic Complications of Primary Biliary Cholangitis

Mariana Zapata, Hendrick Pagan-Torres, Marlyn J. Mayo

CLINICS IN LIVER DISEASE (2024)

Article Gastroenterology & Hepatology

Primary Sclerosing Cholangitis Epidemiology, Diagnosis, and Presentation

Aalam Sohal, Sanya Kayani, Kris Kowdley

Summary: Primary sclerosing cholangitis (PSC) is an immune-mediated liver disease characterized by inflammation and fibrosis of bile ducts. It is commonly associated with inflammatory bowel disease, especially ulcerative colitis. The natural history of the disease varies among patients, but most will develop cirrhosis.

CLINICS IN LIVER DISEASE (2024)